CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity

Michelle E. Ernst, Evan H. Baugh, Amanda Thomas, Louise Bier, Natalie Lippa, Nicholas Stong, Maureen S. Mulhern, Sulagna Kushary, Cigdem I. Akman, Erin L. Heinzen, Raymond Yeh, Weimin Bi, Neil A. Hanchard, Lindsay C. Burrage, Magalie S. Leduc, Josephine S.C. Chong, Renee Bend, Michael J. Lyons, Jennifer A. Lee, Pim SuwannaratEva Brilstra, Marleen Simon, Marije Koopmans, Ellen van Binsbergen, Daniel Groepper, Julie Fleischer, Caroline Nava, Boris Keren, Cyril Mignot, Sophie Mathieu, Grazia M.S. Mancini, Suneeta Madan-Khetarpal, Elena M. Infante, Judith Bluvstein, Andrea Seeley, Kristine Bachman, Eric W. Klee, Laura E. Schultz-Rogers, Linda Hasadsri, Sarah Barnett, Marissa S. Ellingson, Matthew J. Ferber, Vinodh Narayanan, Keri Ramsey, Anita Rauch, Pascal Joset, Katharina Steindl, Theodore Sheehan, Annapurna Poduri, Alejandra Vasquez, Claudia Ruivenkamp, Susan M. White, Lynn Pais, Kristin G. Monaghan, David B. Goldstein, Tristan T. Sands, Vimla Aggarwal

Research output: Contribution to journalArticlepeer-review


CSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow-up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures.

Original languageEnglish (US)
Pages (from-to)e103-e109
Issue number7
StatePublished - Jul 2021


  • CK2
  • CSNK2A1
  • MSNE
  • casein kinase II
  • generalized epilepsy
  • myoclonic seizures
  • myoclonic status epilepticus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity'. Together they form a unique fingerprint.

Cite this